CRISPR-based genome editing in lung organoids has predominantly focused on PSC-stage modifications to model developmental disorders (SFTPB deficiency, Hermansky-Pudlak syndrome)11, 81 and chronic pathologies (IPF, LUAD)75, 82, 83. The gene discussed is SFTPB; the disease is idiopathic pulmonary fibrosis.